炎症性肠病（inflammatory bowel disease，IBD）是一种慢性非特异性肠道炎症性疾病。IBD的发病机制尚未明确，目前西医治疗多使用糖皮质激素、氨基水杨酸及免疫抑制剂等，但其不良反应较多，治疗效果不理想，而中医药治疗具有安全性高且不良反应较少等特点。从中药中寻找治疗IBD的药物已成为热点。白术Atractylodis Macrocephalae Rhizoma为我国传统中药材，含有白术内酯、白术多糖等多种活性成分，具有抗炎、抗氧化、增强免疫、调节胃肠道功能等多种药理作用。白术及其复方治疗IBD具有良好的应用前景，通过查阅国内外相关文献，对白术及其活性成分、白术药对及相关复方治疗IBD的作用机制进行归纳总结，以期为白术及其复方治疗IBD的深入研究和临床应用提供参考。

Inflammatory bowel disease (IBD) is a chronic non-specific inflammatory disease of the intestine. The pathogenesis of IBD has not yet been clarified. Currently, glucocorticosteroids, aminosalicylic acid and immunosuppressant drugs are mostly used in western medical treatment, but they have more adverse effects and the therapeutic effect is unsatisfactory, whereas the treatment of traditional Chinese medicine (TCM) has the characteristics of high safety and fewer adverse effects. Therefore, it has become a hotspot to find drugs from TCM to treat IBD. Baizhu (Atractylodis Macrocephalae Rhizoma) is a traditional Chinese herbal medicine, containing atractylodes lactone, atractylodes polysaccharides and other active ingredients, with anti-inflammatory, antioxidant, immune-enhancing, gastrointestinal function regulation and other pharmacological effects. Atractylodis Macrocephalae Rhizoma and its compound formulas have good application prospects in the treatment of IBD. By referring to relevant literatures at home and abroad, this paper summarized the action mechanism of Atractylodis Macrocephalae Rhizoma and its active ingredients, Atractylodis Macrocephalae Rhizoma medicine pair and related compounds in the treatment of IBD, in order to provide references for further research and clinical application of Atractylodis Macrocephalae Rhizoma and its compounds in the treatment of IBD..

R285

成都中医药大学青基进阶人才专项（QJJJ2023003）;成都中医药大学杏林基金项目（ZRQN2019008）